Erythropoietin and radiotherapy: a dangerous combination?
Dunst
Jürgen
J
D000740:Anemia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D015687:Cell Hypoxia; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D019583:Dose Fractionation, Radiation; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000502:physiology / Q000627:therapeutic use*; D005260:Female; D006258:Head and Neck Neoplasms / Q000097:blood / Q000532:radiotherapy; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000378:metabolism / Q000532:radiotherapy*; D010386:Pelvic Neoplasms / Q000097:blood / Q000532:radiotherapy; D010919:Placebos; D011379:Prognosis; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012306:Risk; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000532:radiotherapy
D006397:Hematinics; D006454:Hemoglobins; D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa